AstraZeneca Pharma India — Peer Comparison

How the peer fair value is calculated and which companies were used as benchmarks.

Peer selection

Peers are selected from the same Branded generics & specialty pharma industry. 8 companies were matched as valid comparables.

Same-industry peers share similar business models, cost structures, and growth prospects — making them the most appropriate benchmarks for valuation multiples.

Peer comparison table

Branded generics & specialty pharma · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
AstraZeneca Pharma India ASTRAZEN · you	₹15,636 Cr	83.4×	17.9×	59.4×	21.5%	8.2%	31.4%
Sector median	—	27.2×	3.7×	20.5×	11.5%	12.9%	14.2%
Cipla CIPLA	₹1.1 L Cr	29.1×	3.3×	20.8×	11.3%	13.8%	7.4%
Zydus Lifesciences ZYDUSLIFE	₹1.1 L Cr	24.6×	4.1×	20.3×	16.7%	16.7%	16.3%
Mankind Pharma MANKIND	₹98,725 Cr	51.7×	6.0×	29.1×	11.7%	13.4%	17.7%
Lupin LUPIN	₹98,260 Cr	19.3×	4.6×	12.3×	23.8%	19.1%	18.9%
Dr Reddy's Laboratories DRREDDY	₹97,644 Cr	25.2×	2.8×	14.8×	11.1%	12.5%	11.0%
Aurobindo Pharma AUROPHARMA	₹83,993 Cr	24.1×	2.2×	12.5×	9.2%	10.4%	10.6%
Glenmark Pharmaceuticals GLENMARK	₹70,973 Cr	48.1×	6.2×	30.2×	13.0%	8.0%	13.6%
Biocon BIOCON	₹67,470 Cr	145.1×	1.9×	25.6×	1.1%	2.3%	14.8%

Peer comparison verdict

AstraZeneca trades at a premium to peers (P/E 83.4× vs median 27.2×), but its higher ROE of 21.5% (sector 11.5%) justifies much of that premium — quality rarely comes cheap.

How the peer fair value is calculated

Three valuation methods are weighted by sector. Each gives a fair value based on how sector peers are currently priced.

Method breakdown

40% weight · 7 peers

Sector median PE25.2×

Fair value via PE₹1,888

20% weight · 8 peers

Sector median PB3.7×

Fair value via PB₹1,289

EV/EBITDA

40% weight · 8 peers

Sector median EV/EBITDA20.5×

Fair value via EV/EBITDA₹2,163

Blended peer fair value₹1,878

Why median? Why these weights?

Median over mean: The sector median is used instead of the average because valuation multiples have extreme outliers — one high-growth company at 200× P/E would dramatically skew a mean. The median gives the middle value in the peer set, which better represents typical pricing.

Sector-specific weights: The weight given to each method reflects what matters most in this sector. For banks, P/B dominates because their value is tied to book assets. For IT companies, P/E carries the most weight because earnings quality matters more than asset base. For capital-intensive businesses, EV/EBITDA accounts for varying debt levels across peers and removes financing structure bias.

Limitations of peer comparison

Peer comparison assumes comparable companies are truly comparable — which is never perfectly true. Sector classifications can be imperfect: a conglomerate classified as "IT" may also have significant manufacturing revenue. Small peer counts (below 5) reduce confidence, as a single outlier can skew the sector median. When the entire sector is broadly expensive, peer comparison will show even an expensive stock as "fairly valued" relative to its peers.

The peer fair value shown is an algorithmic estimate based on publicly available financial data. It is not investment advice or a recommendation to buy, sell, or hold any security. Please consult a SEBI-registered investment adviser before making any investment decision.